3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Bevacizumab
19
Paclitaxel
16
Carboplatin
12
pembrolizumab
11
liposomal doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Gemcitabine
8
olaparib
7
fludarabine
7
Topotecan
7
Magnetic Resonance Spectroscopy
7
Taxes
5
Immunoglobulin G
5
Fulvestrant
5
Disulfides
5
niraparib
4
Oxaliplatin
4
Nivolumab
4
Biopsy
4
trastuzumab deruxtecan
3
palbociclib
3
mirvetuximab soravtansine
3
aldesleukin
3
Leucovorin
3
Fluorouracil
3
1-dodecylpyridoxal
3
ulixertinib
2
nilotinib
2
ipatasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled